Meeting
2022 ASCO Annual Meeting
ALTER-UC-001: Phase II trial of anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma.
Authors
Hailiang Zhang
Department of Urology Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
Hailiang Zhang , Ding-Wei Ye
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT05124431
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4598)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4598
Abstract #
TPS4598
Poster Bd #
89a
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901).
First Author: Ian D. Davis
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
First Author: Zhiwei Chang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.
First Author: Shui-Ling Jin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.
First Author: Ning Li